Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Nov 17, 2022 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
10%+ Owner
Signature
/s/ Wellington Biomedical Innovation Master Investors (Cayman) I L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Peter McIsaac, Title: Authorized Person
Stock symbol
ACRV
Transactions as of
Nov 17, 2022
Transactions value $
$0
Form type
4
Date filed
11/21/2022, 12:22 PM
Previous filing
Nov 9, 2022
Next filing
Mar 27, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Conversion of derivative security +888K 888K Nov 17, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRV Series B Preferred Stock Conversion of derivative security $0 -2.19M -100% $0.00* 0 Nov 17, 2022 Common Stock 888K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) I L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On November 17, 2022, the Series B Preferred Stock automatically converted into Common Stock on a 1-to-2.466 basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The Series B Preferred Stock had no expiration date.